The Duquesne Family Office Q3 2025 Portfolio Report: A Strategic Analysis of Stanley Druckenmiller's Allocation in a Transitioning Macroeconomic Regime

Executive Summary#

The third quarter of 2025 represents a defining inflection point for the Duquesne Family Office, the investment vehicle steered by the legendary macro tactician Stanley Druckenmiller. With managed 13F securities valued at approximately $4.06 billion as of the reporting period ending September 30, 2025, the portfolio exhibits a sophisticated structural rotation that diverges sharply from the consensus trades that dominated the earlier stages of the post-pandemic cycle.¹ The filing reveals a decisive pivot away from pure-play semiconductor valuation expansion toward a barbell strategy anchored by high-conviction biotechnology, applied artificial intelligence, and industrial capacity.

The portfolio remains characteristically concentrated, with the top 10 holdings accounting for 53.93% of total assets, a hallmark of Druckenmiller's investment philosophy which prioritizes deep conviction over broad diversification.² The turnover rate for the quarter was notably high, with a 92.3% turnover and a portfolio comprised of 65 total holdings, reflecting an agile response to shifting liquidity conditions and macroeconomic signals.⁴

This report provides an exhaustive, forensic examination of the fund's composition, the architectural philosophy of its manager, and the granular investment theses driving its largest positions. It dissects the portfolio not merely as a list of stocks, but as a coherent macroeconomic expression betting on the durability of healthcare innovation, the re-industrialization of the Western economy, and the global dominance of specific e-commerce monopolies.

Part I: The Architect - Stanley Druckenmiller and the Duquesne Philosophy#

To decipher the signals embedded in the Q3 2025 13F filing, one must first possess a nuanced understanding of the capital allocator behind the fund. Stanley Druckenmiller is not a traditional stock picker; he is a macro trader who uses equities as instruments to express broader economic views regarding liquidity, growth, and central bank policy.

1.1 The Provenance of a Macro Legend#

Born in Pittsburgh, Pennsylvania, in 1953, Stanley Druckenmiller's ascent in the financial world is grounded in a unique blend of rigorous skepticism and aggressive opportunism.⁶ His career began in 1977 at Pittsburgh National Bank, where his unconventional insights propelled him to the head of the equity research group after only one year-a meteoric rise that foreshadowed his future dominance.⁶ In 1981, he founded Duquesne Capital Management, the firm that would become the primary vehicle for his investment success.⁶

Druckenmiller's renown reached global proportions during his tenure at George Soros's Quantum Fund from 1988 to 2000.⁷ He is widely credited as the intellectual architect behind the 1992 trade that "broke the Bank of England." Recognizing that the British pound sterling was fundamentally overvalued within the European Exchange Rate Mechanism (ERM) and that the Bank of England's defense of the currency was unsustainable, Druckenmiller orchestrated a massive short position against the pound. The trade generated over $1 billion in profits in a single day, cementing his reputation as one of the few investors capable of identifying and capitalizing on systemic central bank misalignments.⁶

For three decades, Druckenmiller delivered an average annual return of approximately 30% without a single down year-a track record of consistency that is virtually unparalleled in the high-volatility world of macro hedge funds.⁹ In 2010, citing the emotional toll of managing outside capital and his desire to maintain his impeccable standards, he returned all client funds and converted Duquesne Capital into a Family Office, which he continues to manage today.⁹

1.2 Core Investment Philosophy: The Logic of the "Pig"#

Druckenmiller's investment style is distinct from the diversification models taught in modern business schools. His philosophy rests on several pillars that are visibly evident in the Q3 2025 portfolio construction.

1.2.1 Liquidity as the Primary Driver#

A central tenet of Druckenmiller's worldview is that earnings do not move the overall market; liquidity does. He has famously stated, "Earnings don't move the overall market; it's the Federal Reserve Board... focus on the movement of liquidity".¹¹ He meticulously tracks central bank balance sheets and interest rate policies, viewing them as the tides that lift or sink all asset classes. In the current 2025 context, his positioning suggests a wariness of the "everything bubble" fueled by fiscal dominance, leading him to seek assets with idiosyncratic drivers-such as biotech-that can perform even if general market liquidity tightens.¹³

1.2.2 The Doctrine of Concentration#

Druckenmiller rejects diversification as a hedge against ignorance. Instead, he subscribes to the Mark Twain aphorism: "Put all your eggs in one basket and watch the basket very carefully".³ He argues that highly concentrated bets decrease risk because they force the investor to be hyper-vigilant. "If you have a big massive position, it has your attention," he has argued.³ This is empirically demonstrated in the current portfolio, where the top five holdings alone represent nearly 40% of the total managed assets.¹⁴

1.2.3 The "Soros" Risk Management Style#

From George Soros, Druckenmiller learned that "it's not whether you're right or wrong that's important, but how much money you make when you're right and how much you lose when you're wrong".¹⁵ This philosophy, often summarized as "being a pig," dictates that when an investor possesses high conviction in a trade, they must size the position aggressively to maximize returns. Conversely, when the thesis breaks, the position must be cut immediately. This explains the fund's high turnover rate and the willingness to exit high-flying names like Nvidia completely when the risk/reward profile shifts, while simultaneously building massive positions in new convictions like Natera.⁴

1.2.4 Mental Flexibility and Agility#

Druckenmiller is noted for his lack of ideological attachment to his positions. He possesses the psychological flexibility to reverse course rapidly-flipping from net long to net short, or rotating sectors entirely, based on new data. This agility allows him to navigate market regime changes that often trap more rigid institutional investors.⁴

Part II: Macroeconomic Context and Strategic Asset Allocation (Q3 2025)#

The composition of the Q3 2025 portfolio cannot be viewed in a vacuum; it is a direct response to the specific macroeconomic conditions of late 2025. The data suggests that Druckenmiller is positioning for a complex environment characterized by sticky inflation, potential economic deceleration (the "hard landing" risk), and a technological transition from infrastructure build-out to application deployment.

2.1 The "Barbell" Structure#

The portfolio exhibits a classic "barbell" structure, balancing defensive, idiosyncratic growth assets against opportunistic, cyclical exposures.

• The Defensive Anchor (Healthcare): Nearly 30% of the portfolio is allocated to healthcare and biotechnology. These companies have demand curves that are largely independent of GDP growth; patients require cancer monitoring and lung disease treatments regardless of interest rates or consumer sentiment. This acts as the portfolio's ballast.¹⁶

• The Aggressive Wing (Tech & Emerging Markets): On the other side, Druckenmiller maintains exposure to high-beta technology stocks (Amazon, Meta) and emerging markets (China/Global via EEM and Coupang). These positions allow the fund to capture upside volatility should the Federal Reserve pivot to aggressive rate cuts or if the global economy re-accelerates.⁵

2.2 The AI Pivot: From Infrastructure to Application#

A defining narrative of the 2024-2025 period for Druckenmiller was his early entry and subsequent exit from Nvidia. While he rode the initial wave of the AI infrastructure boom, his Q3 2025 filings confirm a continued rotation out of pure hardware plays (selling Nvidia, reducing manufacturing equipment exposure) and into the beneficiaries of that infrastructure.

The thesis appears to be that the "pick and shovel" phase of the AI gold rush has become overcrowded and priced for perfection. The next phase of value creation lies with the companies that utilize this compute power to generate tangible business outcomes-companies like Meta Platforms (using AI for ad targeting), Amazon (using AI for logistics and cloud dominance), and Natera (using advanced computation for genomic analysis).13

2.3 Portfolio Metrics and Concentration#

The table below highlights the structural concentration of the portfolio as of September 30, 2025.²

This turnover rate of 92.3% is exceptionally high, underscoring Druckenmiller's active trading style and his willingness to aggressively reposition the book as market conditions evolve.⁴

Part III: The Healthcare Conviction - A Deep Dive into the Portfolio Anchor#

The most significant signal in the Q3 2025 filing is the overwhelming conviction in the healthcare sector. Druckenmiller has allocated his three largest positions to this space, signaling a belief that bio-innovation offers the most attractive risk-adjusted returns in the current market.

3.1 Natera Inc. (NTRA) - The Crown Jewel#

• Position Size: 3,214,532 shares

• Market Value: ~$517.44 million

• Portfolio Weight: 12.74%

• Q3 Activity: Increased position by 4.19%.⁵

The Business Model:

Natera is a global leader in cell-free DNA (cfDNA) testing, operating at the intersection of biotechnology and data science. The company's technology allows for non-invasive detection of genetic anomalies via blood tests (liquid biopsies). Its business segments cover Women's Health (prenatal screening), Organ Health (transplant rejection), and Oncology (cancer recurrence monitoring).18

The Investment Thesis:

The massive allocation to Natera is driven by the paradigm shift in oncology monitoring known as Signatera.

1. Molecular Residual Disease (MRD): Traditionally, cancer recurrence is monitored via CT/MRI scans, which can only detect tumors once they reach a visible size. Signatera, a personalized blood test, tracks patient-specific tumor mutations in the blood. It can detect recurrence months or even years before imaging, allowing for earlier intervention. This is rapidly becoming the standard of care for colorectal, bladder, and other cancers.¹⁸

2. Prospera & Organ Health: The company's Prospera test assesses kidney transplant rejection risk with greater sensitivity than traditional creatinine tests. Medicare coverage and reimbursement for these tests have expanded, providing a stable revenue tailwind.¹⁹

3. Moat & Network Effects: Natera has processed over 12 million tests, creating a massive genomic dataset that refines its algorithms, creating a barrier to entry for competitors. The "flywheel" of more data leading to better accuracy, leading to more clinician adoption, is in full effect.¹⁸

Druckenmiller's View:

Natera represents a classic "home run" swing. By increasing his stake to nearly 13% of the portfolio, Druckenmiller is betting that Natera will dominate the multi-billion dollar MRD market. The addition of Call options on Natera further leverages this conviction, suggesting he anticipates near-term catalysts, such as earnings beats or expanded guideline inclusion.16

3.2 Insmed Inc. (INSM) - The Binary Event Winner#

• Position Size: 2,420,000 shares

• Market Value: ~$349.00 million

• Portfolio Weight: 8.88%

• Q3 Activity: Increased position by 7.54%.⁵

The Business Model:

Insmed is a biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases. Its commercial focus has been on respiratory conditions, specifically through its drug ARIKAYCE for MAC lung disease.21

The Investment Thesis:

The thesis for Insmed centers on Brensocatib (brand name Brinsupri).

1. Regulatory Victory: In August 2025, the FDA approved Brinsupri as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease characterized by widened airways and frequent infections.²² Prior to this, NCFB patients had no approved therapies, representing a massive unmet medical need with an addressable population of approximately 500,000 in the U.S. alone.²²

2. Mechanism of Action: Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor. It works by reducing the levels of neutrophil serine proteases, which are key drivers of inflammation in the lungs. This targets the root cause of the exacerbations rather than just treating symptoms.²²

3. Commercial Runway: With FDA approval secured and positive opinions from European regulators (CHMP), the risk profile of the stock has shifted from clinical/regulatory risk to commercial execution. Analysts project significant revenue ramps, with estimates of $700 million in sales for the upcoming year.²³

Druckenmiller's View:

The 7.5% increase in share count during Q3-likely post-approval or in anticipation of the commercial launch trajectory-indicates Druckenmiller believes the market is underestimating the peak sales potential of Brinsupri. He views this as a de-risked asset with a clear path to becoming a blockbuster drug.21

3.3 Teva Pharmaceutical Industries (TEVA) - The Deep Value Turnaround#

• Position Size: 16,590,000 shares

• Market Value: ~$335.20 million

• Portfolio Weight: 8.53%

• Q3 Activity: Increased position by 3.91%.⁵

The Business Model:

Teva is one of the world's largest generic pharmaceutical manufacturers, with a growing portfolio of specialty innovative medicines.

The Investment Thesis:

Teva acts as the "value" component of the healthcare basket.

1. Debt Reduction & Litigation Settlement: For years, Teva's stock was depressed by a massive debt load from the Actavis acquisition and looming opioid litigation. By 2025, the company has largely resolved the legal overhangs and has been using cash flow to aggressively deleverage the balance sheet.¹³

2. Pivot to Innovation: Teva is moving beyond low-margin generics into higher-margin innovative drugs, such as Austedo (for Huntington's disease and tardive dyskinesia) and Ajovy (for migraines). The growth of these franchises is re-rating the stock's multiple.¹³

3. Biosimilars: Teva is well-positioned to capitalize on the wave of biosimilars coming to market, leveraging its manufacturing scale.

Druckenmiller's View:

This is a classic "good company, bad balance sheet" fix. As the balance sheet improves, the equity stub value expands disproportionately. It provides a lower-volatility, cash-generative counterweight to the growth-focused Natera and Insmed positions.

3.4 Verona Pharma (VRNA) - The Commercial Launch Play#

• Position Size: 1,000,000 shares

• Market Value: ~$106.93 million

• Portfolio Weight: 2.72%

• Q3 Activity: No change.⁵

The Investment Thesis:

Verona Pharma focuses on respiratory diseases. Its flagship product, Ohtuvayre (ensifentrine), was approved by the FDA in June 2024 for the maintenance treatment of COPD.24

1. Novel Mechanism: Ohtuvayre is a dual inhibitor of PDE3 and PDE4, combining bronchodilator and anti-inflammatory effects in a single molecule. This is the first novel mechanism for COPD in over 20 years.²⁴

2. Launch Trajectory: Q3 2025 data indicates a strong commercial launch, with estimated net product sales of $36 million for the quarter and over 16,000 prescriptions filled.²⁵ The drug is gaining traction among physicians for patients who are not adequately controlled on existing therapies.

Druckenmiller's View:

Similar to Insmed, this is a bet on a successful product launch in a large disease market (COPD). The fact that he held the position steady suggests satisfaction with the early launch metrics.

3.5 NewAmsterdam Pharma (NAMS) - The Next Frontier in Cardiovascular#

• Position Size: 1,923,700 shares

• Market Value: ~$54.71 million

• Portfolio Weight: 1.39%

• Q3 Activity: Added significantly (+131%).²⁶

The Investment Thesis:

NewAmsterdam is developing Obicetrapib, a CETP inhibitor for lowering LDL cholesterol.

1. The CETP Graveyard: Historically, CETP inhibitors (like those from Pfizer and Merck) failed in late-stage trials due to safety issues or lack of efficacy. However, Obicetrapib is a potent, low-dose, next-generation inhibitor that has shown massive LDL reductions (up to 41%) without the off-target effects of predecessors.²⁷

2. Clinical Data: Phase 3 trials (BROADWAY, BROOKLYN) have shown statistically significant LDL lowering and, crucially, potential benefits in Alzheimer's risk reduction (ApoE4 pathway).²⁷

3. Oral Alternative: It offers a potent oral alternative to injectable PCSK9 inhibitors, which suffer from lower patient compliance.

Druckenmiller's View:

The aggressive addition (+131%) in Q3 suggests Druckenmiller believes the Phase 3 data validates the science and that the market's skepticism regarding the CETP class is unwarranted for this specific molecule.

Part IV: The Technology Core - Infrastructure and Applications#

Druckenmiller's technology strategy has evolved from a focus on the hardware "arms dealers" to the dominant platforms that will monetize AI utility.

4.1 Taiwan Semiconductor Manufacturing Co. (TSM) - The Monopoly#

• Position Size: 765,090 shares

• Market Value: ~$213.68 million

• Portfolio Weight: 5.44%

• Q3 Activity: No Change.⁵

The Investment Thesis:

TSMC holds a de facto monopoly on advanced node semiconductor manufacturing. Whether the winner of the AI chip war is Nvidia, AMD, Apple, or Amazon (with its own chips), they all must manufacture at TSMC. This makes TSM the ultimate toll-taker of the digital economy.

• Valuation vs. Nvidia: Unlike Nvidia, which trades at an aggressive multiple of sales, TSMC trades at a more modest valuation relative to its critical importance. Druckenmiller views this as a safer way to play the secular growth of compute power without the valuation risk of the designers.¹³

4.2 Amazon.com Inc. (AMZN) - The Cloud and Commerce Giant#

• Position Size: 437,070 shares

• Market Value: ~$95.97 million

• Portfolio Weight: 2.44%

• Q3 Activity: New Position.⁵

The Investment Thesis:

Druckenmiller re-entered Amazon in Q3, likely driven by two factors:

1. AWS & AI: While Microsoft took the early AI lead, Amazon Web Services (AWS) remains the cloud volume leader. AWS is aggressively deploying its own AI chips (Trainium and Inferentia), offering a cost-effective alternative to Nvidia-based clusters for its clients.

2. Retail Margins: Amazon's reorganization of its fulfillment network into regional hubs has structurally lowered its cost to serve, driving retail margins higher.

3. Valuation: Relative to the "Magnificent Seven," Amazon's valuation in late 2025 appeared attractive to Druckenmiller given its free cash flow acceleration.²⁸

4.3 Meta Platforms (META) - The Efficiency Play#

• Position Size: 76,100 shares

• Market Value: ~$55.89 million

• Portfolio Weight: 1.42%

• Q3 Activity: New Position.⁵

The Investment Thesis:

Meta is the cheapest of the mega-cap tech stocks on a P/E basis. Its open-source AI strategy (Llama models) is effectively commoditizing the LLM layer while improving its core ad-targeting engine. The investment reflects confidence in Zuckerberg's "efficiency" mandate and the company's ability to monetize AI through improved ad conversion and user retention on Reels.28

4.4 DocuSign Inc. (DOCU) - The SaaS Turnaround#

• Position Size: 1,690,000 shares

• Market Value: ~$121.54 million

• Portfolio Weight: 3.09%

• Q3 Activity: Increased by 30.65%.⁵

The Investment Thesis:

DocuSign is evolving from a simple e-signature company to a broader "Intelligent Agreement Management" (IAM) platform. The thesis likely rests on the company's ability to use AI to analyze and manage contracts, moving up the value chain. Additionally, with strong free cash flow and a depressed valuation, it remains a perpetual candidate for private equity buyout or acquisition.16

Part V: Global E-Commerce and The Consumer#

Druckenmiller is betting on regional dominance in the global e-commerce landscape. He prefers companies that have won their specific geographies and are now reaping the benefits of scale.

5.1 Coupang Inc. (CPNG) - The Amazon of Asia#

• Position Size: 4,630,000 shares

• Market Value: ~$149.19M

• Portfolio Weight: 3.79%

• Q3 Activity: Increased by 12.85%.⁵

The Business Model:

Coupang dominates the South Korean e-commerce market with its end-to-end logistics network, similar to Amazon but with even faster delivery metrics ("Dawn Delivery").

The Investment Thesis:

1. Korean Dominance: Coupang has effectively won the Korean market. As its heavy capex cycle concludes, margins are expanding rapidly.

2. Taiwan Expansion: The company is successfully exporting its model to Taiwan, a market with similar density and demographics to Korea, providing a new growth engine.²⁹

3. AI Logistics: Coupang is heavily investing in AI to automate fulfillment centers (driverless forklifts, sorting robots), which further drives down unit costs and widens the moat against competitors.³⁰

5.2 MercadoLibre Inc. (MELI) - The Latin American Juggernaut#

• Position Size: 58,340 shares

• Market Value: ~$136.35 million

• Portfolio Weight: 3.47%

• Q3 Activity: Increased by 8.6%.⁵

The Investment Thesis:

MercadoLibre is a dual-threat: it is both the dominant e-commerce retailer and the leading fintech (Mercado Pago) in Latin America.

1. Logistics Moat: Its logistics network in Brazil and Mexico is unmatched, enabling faster delivery times that competitors cannot replicate.

2. Fintech Growth: Mercado Pago has evolved from a payment processor to a full digital bank, providing credit and financial services to the region's massive unbanked population. This segment is growing faster than the commerce business and has higher margins.³²

5.3 StubHub Holdings (STUB) - The Experience Economy#

• Position Size: 4,260,000 shares

• Market Value: ~$71.73 million

• Portfolio Weight: 1.82%

• Q3 Activity: New Position.²

The Investment Thesis:

StubHub operates in a duopoly with Ticketmaster in the secondary ticket market. Despite inflationary pressures, consumer spending on experiences (concerts, sports) has proven remarkably resilient (the "Taylor Swift effect"). StubHub is a highly cash-generative business with pricing power. Druckenmiller's entry here is a bet on the durability of the experience economy over physical goods consumption.34

Part VI: Industrials, Energy, and Financial Innovation#

The final pillar of the portfolio addresses the physical economy: the need for power, industrial control, and efficient financial plumbing.

6.1 Woodward Inc. (WWD) - Aerospace & Energy Control#

• Position Size: 633,010 shares

• Market Value: ~$159.97 million

• Portfolio Weight: 4.07%

• Q3 Activity: Reduced by 25.43%.⁵

The Business Model:

Woodward provides energy control solutions (valves, actuators, fuel nozzles) for the aerospace and industrial markets.

The Investment Thesis:

1. Aerospace Supercycle: The demand for new aircraft remains at record highs as airlines upgrade fleets post-pandemic. Woodward is a key supplier to both GE and Pratt & Whitney engines.³⁶

2. Power Generation: Its industrial segment serves the power generation market, which is seeing renewed demand due to the electrification needs of data centers and grid modernization.37 > Activity Note: The 25% reduction suggests profit-taking after a strong run, though it remains a top 5 holding.

6.2 Wabtec (WAB) - Rail Efficiency#

• Position Size: 302,410 shares

• Market Value: ~$60.62 million

• Portfolio Weight: 1.54%

• Q3 Activity: Added significantly (+77%).⁵

The Investment Thesis:

Wabtec is a leader in freight and transit rail. The thesis relies on the "Green Friction" trade-rail is the most fuel-efficient way to move freight. As logistics supply chains onshore and decarbonize, rail volumes and the need for modern, efficient locomotives increase. Wabtec's backlog of over $8 billion provides high visibility into future revenue.38

6.3 Figure Technology Solutions (FIGR) - Blockchain Fintech#

• Position Size: 2,120,000 shares

• Market Value: ~$76.99 million

• Portfolio Weight: 1.96%

• Q3 Activity: New Position.⁵

The Business Model:

Figure utilizes the Provenance Blockchain to revolutionize the home equity lending market. Traditional Home Equity Lines of Credit (HELOCs) take weeks to approve; Figure cuts this to days or minutes by using blockchain as an immutable ledger for title and lien recording.39

The Investment Thesis:

With mortgage rates high, homeowners are "locked in" to their low-rate primary mortgages and cannot refinance. To access their home equity (which is at record highs), they must use HELOCs. Figure provides the most efficient "rails" for this product, disrupting legacy banks. Druckenmiller participated in the IPO/funding, signaling a belief in blockchain's utility for real-world asset (RWA) tokenization.41

Part VII: Macro Hedges and Risk Management#

No Druckenmiller portfolio is complete without discussing the hedges. The 13F reveals how he protects the portfolio against his own macroeconomic concerns.

7.1 Emerging Markets (EEM) - The Dollar Hedge#

• Position: $101.46M (2.58% of portfolio)

• Thesis: Druckenmiller has expressed concern over the U.S. fiscal trajectory and the long-term status of the dollar. Buying the iShares MSCI Emerging Markets ETF is a way to bet on global growth outside the U.S. and potentially benefit from a weakening dollar cycle, which disproportionately aids emerging economies.⁵

7.2 Options Strategy - Upside Protection#

The filing shows Call options on SPY (S&P 500) and IWM (Russell 2000).¹⁶

• Mechanism: These options allow the fund to participate in a "melt-up" scenario (where markets rally irrationally due to liquidity) without committing full capital to the indices. It creates defined-risk exposure to the upside while the bulk of the capital sits in high-conviction single names.

Part VIII: Conclusion#

The Q3 2025 filing of the Duquesne Family Office offers a masterclass in asymmetric portfolio construction. Stanley Druckenmiller has pivoted away from the crowded "AI Hardware" trade, foreseeing a maturation of the infrastructure cycle. In its place, he has constructed a fortress of Healthcare Innovation, betting nearly a third of his capital that companies like Natera and Insmed will deliver value through scientific breakthroughs regardless of the GDP print.

Simultaneously, he has deployed capital into the "Users of Tech"-Amazon, Meta, and Coupang-who are best positioned to monetize the new digital era. He balances these growth engines with deep value turnarounds in Teva and industrial capacity in Woodward and Wabtec.

For the professional observer, the signal is clear: The era of "buy everything" is over. We have entered a market of dispersion, where alpha will be generated not by broad beta exposure, but by identifying specific, idiosyncratic business transformations-and having the conviction, like a true "pig," to bet the ranch when the odds are in your favor.

Stanley Druckenmiller's portfolio is not a passive collection of stocks; it is an active, aggressive, and highly curated expression of a specific worldview-one that sees the future belonging to those who cure disease, optimize logistics, and own the platforms of tomorrow.

Works cited#

1. Duquesne Family Office LLC Portfolio Holdings - Fintel, accessed January 3, 2026, https://fintel.io/i/duquesne-family-office-llc

2. DUQUESNE FAMILY OFFICE LLC Top 13F Holdings - WhaleWisdom, accessed January 3, 2026, https://whalewisdom.com/filer/duquesne-family-office-llc

3. 30 Stanley Druckenmiller Quotes Every Investor Should Know - TraderLion, accessed January 3, 2026, https://traderlion.com/quotes/druckenmiller-quotes/

4. Duquesne Family Office 13F Q3 2025: Top Holdings & Recent Moves - Value Sense Blog, accessed January 3, 2026, https://blog.valuesense.io/stanley-druckenmiller-duquesne-family-office-llc-portfolio-q22025-top-holdings-recent-changes/

5. Duquesne Family Office Portfolio | Stanley Druckenmiller 13F ..., accessed January 3, 2026, https://hedgefollow.com/funds/Duquesne+Family+Office

6. Stanley Druckenmiller - Wikipedia, accessed January 3, 2026, https://en.wikipedia.org/wiki/Stanley_Druckenmiller

7. Stanley Druckenmiller - Duquesne Family Office - Forbes, accessed January 3, 2026, https://www.forbes.com/profile/stanley-druckenmiller/

8. Famous Traders and Their Strategies: Episode 2 - Stanley Druckenmiller - Orbex Forex Trading Blog, accessed January 3, 2026, https://www.orbex.com/blog/en/2018/02/famous-traders-and-their-strategies-stanley-druckenmiller

9. accessed January 3, 2026, https://247wallst.com/investing/2025/05/19/billionaire-stan-druckenmiller-shaves-660-m-off-his-book-and-jumps-into-these-stocks/#:~:text=After%2030%20years%20of%20delivering,he%20continues%20to%20run%20today.

10. Billionaire Stanley Druckenmiller Just Went All in on AI, Buying Amazon, Meta Platforms, and Alphabet. Could AI Stocks Still Deliver Big Returns in 2026? | Nasdaq, accessed January 3, 2026, https://www.nasdaq.com/articles/billionaire-stanley-druckenmiller-just-went-all-ai-buying-amazon-meta-platforms-and

11. Why a December Fed Cut Will Reignite the 2025 Bull Market - Nasdaq, accessed January 3, 2026, https://www.nasdaq.com/articles/why-december-fed-cut-will-reignite-2025-bull-market

12. Stanley Druckenmiller | PDF | Stocks | Federal Reserve - Scribd, accessed January 3, 2026, https://www.scribd.com/document/865894440/Stanley-Druckenmiller

13. Billionaire Stanley Druckenmiller Has Exited His Fund's Positions in Nvidia and Palantir, and Has Consistently Invested in These 2 Outstanding Stocks for Four Consecutive Quarters | Bitget News, accessed January 3, 2026, https://www.bitget.com/news/detail/12560605002718

14. Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2025 Update, accessed January 3, 2026, https://money.tmx.com/quote/DAKT:US/news/7690013764515485/Tracking_Stanley_Druckenmillers_Duquesne_Family_Office_Portfolio_Q3_2025_Update

15. Lessons from Stanley Druckenmiller - Antoine Buteau, accessed January 3, 2026, https://www.antoinebuteau.com/lessons-from-stanley-druckenmiller/

16. Stanley Druckenmiller's Q3 2025 Portfolio: Healthcare Conviction Meets Macro Hedging, accessed January 3, 2026, https://www.voronoiapp.com/investing/Stanley-Druckenmillers-Q3-2025-Portfolio-Healthcare-Conviction-Meets-Macro-Hedging-7208

17. Billionaire Stanley Druckenmiller's buys point to tech stock shift - TheStreet, accessed January 3, 2026, https://www.thestreet.com/investing/stanley-druckenmillers-latest-buys-suggest-shifting-tech-trend

18. Natera: A global leader in cell-free DNA testing, accessed January 3, 2026, https://www.natera.com/

19. Prospera FAQ | Natera, accessed January 3, 2026, https://www.natera.com/organ-health/prospera-organ-transplantation-assessment/faq/

20. Prospera - Blood Test for Kidney Transplant Rejection - Natera, accessed January 3, 2026, https://www.natera.com/organ-health/prospera-organ-transplantation-assessment/

21. INSM Stock Up 78% in 6 Months: Here's What You Need to Know, accessed January 3, 2026, https://www.tradingview.com/news/zacks:bfc29e528094b:0-insm-stock-up-78-in-6-months-here-s-what-you-need-to-know/

22. FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease - Aug 12, 2025 - Investor Relations | Insmed Incorporated, accessed January 3, 2026, https://investor.insmed.com/2025-08-12-FDA-Approves-BRINSUPRI-TM-brensocatib-as-the-First-and-Only-Treatment-for-Non-Cystic-Fibrosis-Bronchiectasis,-a-Serious,-Chronic-Lung-Disease

23. Insmed's 'win streak' ends as top drug fails study in chronic nasal condition, accessed January 3, 2026, https://www.biopharmadive.com/news/insmed-brensocatib-birch-rhinosinusitis-study-results/808251/

24. Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine), accessed January 3, 2026, https://www.veronapharma.com/news/verona-pharma-announces-us-fda-approval-of-ohtuvayre-ensifentrine/

25. Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights - GlobeNewswire, accessed January 3, 2026, https://www.globenewswire.com/news-release/2025/01/07/3005151/0/en/Verona-Pharma-Reports-Strong-Ohtuvayre-Launch-and-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2024-Financial-Highlights.html

26. Duquesne Family Office LLC 13F Stock Portfolio Holdings - Inside Arbitrage, accessed January 3, 2026, https://www.insidearbitrage.com/holdings/0001536411/duquesne-family-office-llc/

27. Learn About Obicetrapib From NewAmsterdam Pharma, accessed January 3, 2026, https://www.newamsterdampharma.com/obicetrapibta8995/

28. Billionaire Stanley Druckenmiller Just Bought These 3 AI Stocks. Should Investors Follow Suit? | The Motley Fool, accessed January 3, 2026, https://www.fool.com/investing/2025/11/22/billionaire-stanley-druckenmiller-just-bought-thes/

29. Coupang, Inc. (CPNG): A Bull Case Theory - Finviz, accessed January 3, 2026, https://finviz.com/news/199609/coupang-inc-cpng-a-bull-case-theory

30. U.S. Technology Company Coupang Presents Its Vision to Accelerate AI-driven Commerce at the APEC CEO Summit, accessed January 3, 2026, https://ir.aboutcoupang.com/news-events/news/news-details/2025/U-S--Technology-Company-Coupang-Presents-Its-Vision-to-Accelerate-AI-driven-Commerce-at-the-APEC-CEO-Summit/default.aspx

31. Coupang Unveils $3 Billion AI-Driven Commerce Expansion,... - Market Chameleon, accessed January 3, 2026, https://marketchameleon.com/articles/b/2025/10/29/coupang-ai-investment-global-commerce-exports

32. What 2025 Tells Us About MercadoLibre's Long-Term Story | The Motley Fool, accessed January 3, 2026, https://www.fool.com/investing/2025/12/30/what-2025-tells-us-about-mercadolibres-long-term/

33. Mercado Libre's Strategic Investments Drive Net Revenue to $7.4 Billion in Q3 2025, Marking the 27th Consecutive Quarter of Growth Above 30% YoY, accessed January 3, 2026, https://investor.mercadolibre.com/news-and-events/mercado-libres-strategic-investments-drive-net-revenue-74-billion-q3-2025-marking-27th-consecutive-quarter-growth-above-30-yoy

34. Stanley Druckenmiller's Trades and Holdings in Q3 2025 - Daniel Scrivner, accessed January 3, 2026, https://www.danielscrivner.com/stanley-druckenmiller-trades-and-holdings-q3-2025/

35. Stan Druckenmiller Overhauls His Family Office's U.S. Stock Portfolio | Institutional Investor, accessed January 3, 2026, https://www.institutionalinvestor.com/article/stan-druckenmiller-overhauls-his-family-offices-us-stock-portfolio

36. Woodward, Inc. - Wikipedia, accessed January 3, 2026, https://en.wikipedia.org/wiki/Woodward,_Inc.

37. Woodward Fact Sheet, accessed January 3, 2026, https://www.woodward.com/wp-content/uploads/sites/2/2024/09/WWD-Fact-Sheet-2024_Farnborough-Airshow.pdf

38. How Does Wabtec Company Work? - PESTEL Analysis, accessed January 3, 2026, https://pestel-analysis.com/blogs/how-it-works/wabteccorp

39. Figure Goes Public As HELOC Growth, Marketplace Vision Take Center Stage, accessed January 3, 2026, https://nationalmortgageprofessional.com/news/figure-goes-public-heloc-growth-marketplace-vision-take-center-stage

40. Figure Technology Targets $2T Consumer Lending Market With Blockchain and AI, accessed January 3, 2026, https://www.pymnts.com/consumer-finance/2025/figure-technology-targets-2t-consumer-lending-market-with-blockchain-and-ai/

41. Form S-1 - SEC.gov, accessed January 3, 2026, https://www.sec.gov/Archives/edgar/data/2064124/000162828025041443/figuretechnologysolutionsi.htm

42. Blockchain-powered lending platform Figure Technology sets terms for $500 million IPO, accessed January 3, 2026, https://www.renaissancecapital.com/IPO-Center/News/113150/Blockchain-powered-lending-platform-Figure-Technology-sets-terms-for-$500-m